INJECTION SOLUTION COMPRISING A NON-NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR AND POLY(LACTIDE-CO-GLYCOLIDE)
An injection solution contains an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent and a pharmaceutical active ingredient which is non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups. The content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.
1 . An injection solution, comprising:
an organic solvent,
a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and
a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups,
wherein a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution; and
wherein said pharmaceutical active ingredient is not Etravirine, Rilpivirine, Doravirine or Dolutegravir.
2 . The injection solution according to claim 1 , wherein the organic solvent is at least one member selected from the group consisting of N-methyl-2-pyrrolidone, ethanol, propylene glycol, 2-pyrrolidone, acetone, methyl acetate, ethyl acetate, methyl ethyl ketone, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, caprolactam, decylmethylsulfoxide, a fatty acid, and 1-dodecylazacycloheptan-2-one.
3 . The injection solution according to claim 1 , wherein the copolymer is a poly(lactide-co-glycolide) with a molar ratio of lactide:glycolide from about 80:20 to about 40:60.
4 - 5 . (canceled)
6 . An injection dispersion, comprising:
the injection solution according to claim 1 as continuous phase, and
a further pharmaceutical active ingredient which is dispersed therein.
7 . The injection dispersion according to claim 6 , wherein the further pharmaceutical active ingredient is at least one member selected from the group consisting of a further non-nucleoside reverse transcriptase inhibitor, a nucleoside reverse transcriptase inhibitor, and an integrase inhibitor.
8 . A process for preparing the injection solution according to claim 1 , the process comprising:
combining the organic solvent in sterile form, the pharmaceutical active ingredient in sterile form and the copolymer in sterile form in a sterile injection device.
9 . A kit, comprising:
an organic solvent,
a pharmaceutical active ingredient which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, and
wherein said pharmaceutical active ingredient is not Etravirine, Rilpivirine, Doravirine or Dolutegravir, and
a copolymer which is a poly(lactide-co-glycolide) in sterile form,
wherein the pharmaceutical active ingredient and the copolymer are present in dry form in a sterile injection device and the organic solvent is kept separately and can be added into the injection device subsequently.
10 . (canceled)
11 . A pharmaceutical dosage form, comprising:
the injection solution according to claim 1 .
12 . A kit, which comprises:
the pharmaceutical dosage form according to claim 11 ,
at least one nucleoside reverse transcriptase inhibitor (NRTI),
at least one non-nucleoside reverse transcriptase inhibitor (NNRTI), and
optionally a booster, which is a liver enzyme inhibitor.
13 . A triple therapy method of treating a subject with an antiretroviral HIV treatment, the method comprising:
injecting the injection solution according to claim 1 , combined with daily oral fixed dose formulations of at least one nucleoside reverse transcriptase inhibitor or at least one further non-nucleoside reverse transcriptase inhibitor or both and optionally with a booster, which is a liver enzyme inhibitor, into a subject in need thereof.
14 . The method according to claim 13 , wherein the non-nucleoside reverse transcriptase inhibitor is present and is at least one member selected from the group consisting of Efavirenz, Nevirapine, and Delavirdine.
15 . The method according to claim 13 , wherein the nucleoside reverse transcriptase inhibitor is present and at least one member selected from the group consisting of Abacavir, Emtricitabine, Didanosine, Zidovudine, Apricitabine, Stampidine, Elvucitabine, Racivir, Amdoxovir, Stavudine, Tenofovir, Zalcitabine, and Festinavir.
16 . The method according to claim 13 , wherein, in the method the following pairs of nucleoside reverse transcriptase inhibitors and/or non-nucleoside reverse transcriptase inhibitors are included: Lamivudine and Zidovudine, Lamivudine and Tenofovir, and Lamivudine and Efavirenz.
17 . A pharmaceutical dosage form, comprising:
the injection dispersion according to claim 6 .
18 . The injection solution according to claim 1 , wherein a concentration of copolymer in the organic solvent is 5-30 wt. %.
19 . The kit according to claim 9 , wherein an amount of solvent and copolymer provide for a concentration of copolymer in the organic solvent of 5-30 wt. %.